Skip to main content
SpringerLink
Log in

Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol

Rheumatology International volume 28, pages 103–111 (2007)Cite this article

Abstract

While in other chronic diseases combined treatment regimens are the rule there is a lack of reported experience or study data on combining different specific drugs to treat osteoporosis. Significant differences in the mode of action (MOA) of the substances to be combined may be important for achieving optimal therapeutic results. Recognising that today bisphosphonates are the leading therapy for osteoporosis we suggest that the active D-hormone analog alfacalcidol with its completely different mechanisms of action could be an interesting combination to improve the therapeutic outcome of the pure antiresoptive action of bisphosphonates. Alfacalcidol is activated by the enzyme 25-hydroxylase in the liver for systemic and in osteoblasts for local D-hormone actions. It possesses a unique pattern of pleiotropic effects on, e.g. gut, bone, pararthyroids, muscle and brain. Alfacalcidol is superior to plain vitamin D (cholecalciferol) because the final kidney activation of the latter is regulated by a negative feedback mechanism. In vitamin D replete patients or patients with impaired kidney function no increased D-hormone action at the target tissues can be achieved. Animal studies and several trials in humans with alendronate plus calcitriol or alfacalcidol proved that the combination induced significantly higher increases of bone mineral density (BMD) than the respective mono-therapies. The results of the 2-year AAC-trial from our group indicate that the combination alendronate and alfacalcidol is also superior in terms of falls, fractures and back pain. From the review of the literature and the own new results we conclude that this combined therapeutic regimen is a very promising option for treating established osteoporosis and propose a differentiated use of alfacalcidol alone or the combination with alendronate in different stages and clinical situations of osteoporosis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (Canada)

Fig. 1
Fig. 2
Fig. 3

References

  1. Ringe JD (2000) Perspectives of combined treatment strategies in osteoporosis. J Menopause 7(Suppl 2):22–23

    Google Scholar 

  2. Alexandersen P, Riis BJ, Christiansen C (1999) Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocriol Metab 84:3013–3020

    Article  CAS  Google Scholar 

  3. Gambacciani M, Spinetti A, Cappagli B, Ciaponi M, Gallo R, Rovati LC, Genazzani AR (1995) Effects of low-dose monofluorophosphate and transdermal oestradiol on postmenopausal vertebral bone loss. Eur Menopause J 2:16–20

    Google Scholar 

  4. Ringe JD, Setnikar I (2002) Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study. Rheumatol Int 22:27–32

    Article  PubMed  CAS  Google Scholar 

  5. Lems WF, Jacobs JWG, Bijlsma WJ, van Veen GJM, Houben HHML, Haanen HCM, Gerrits MI, van Rijn HJM (1997) Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticoid induced osteoporosis? Ann Rheumatol Dis 56:357–363

    Article  CAS  Google Scholar 

  6. Ringe JD, Rovati L (2001) Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 69:252–255

    Article  PubMed  CAS  Google Scholar 

  7. Morabito N, Gaudio A, Lasco A, Vergara C, Tallarida F, Crisafulli G, Trifiletti A, Cincotta M, Pizzoleo MA, Frisina N (2003) Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 14:500–506

    Article  PubMed  CAS  Google Scholar 

  8. Ringe JD, Dorst A, Faber H, Kipshoven C, Rovati LC, Setnikar I (2005) Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study. Rheumatol Int 25:296–300

    Article  PubMed  CAS  Google Scholar 

  9. Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T (2003) Effect of raloxifene combined with monofluoro-phosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 14:741–749

    Article  PubMed  CAS  Google Scholar 

  10. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH (1995) The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronat. Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603–610

    Article  PubMed  CAS  Google Scholar 

  11. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxseri ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215

    Article  PubMed  CAS  Google Scholar 

  12. Frediani B, Allegri A, Bisohno S, Marcolongo R (1998) Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest 14:235–244

    Article  Google Scholar 

  13. Ringe JD (2006) Alfacalcidol in prevention and treatment of all major forms of osteoporosis and renal osteopathy. Georg Thieme, Stuttgart

    Google Scholar 

  14. McKenna MJ (1992) Differences in vitamin D status between countries in young adults and the elderly. Am J Med 93:69–77

    Article  PubMed  CAS  Google Scholar 

  15. Chapuy MC, Schott AM, Garnero P, Hans D, Delmas P, Meunier PJ (1996) Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. J Clin Endocrinol Metab 81:1129–1133

    Article  PubMed  CAS  Google Scholar 

  16. Burckhardt P, Krieg MA, Gerber S, Burnand B, Thièbaud D (1996) Vitamin D: metabolism and specific role in the elderly. In: Ringe JD, Meunier PJ (eds) Osteoporotic fractures in the elderly. Thieme, Stuttgart pp 25–36

    Google Scholar 

  17. Krexner E, Resch H, Pietschmann P, Bernecker P, Woloscuk W, Vukovich T, Geyer G, Willvonseder R (1996) Vitamin D status in residents of a long-term-care geriatric hospital in Vienna. Osteologie 5:13–18

    Google Scholar 

  18. Chapuy MC, Arlot ME, DuBoef F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642

    Article  PubMed  CAS  Google Scholar 

  19. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 337:670–676

    Article  PubMed  CAS  Google Scholar 

  20. Lips P, Graafsmans WC, Ooms ME, Bezemer PD, Bouter LM (1996) Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med 124:400–406

    PubMed  CAS  Google Scholar 

  21. Papadimitropoulos E, Wells G, Shea B (2002) Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560–569

    Article  PubMed  CAS  Google Scholar 

  22. The RECORD Trial group (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium OR vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621–1628

    Article  CAS  Google Scholar 

  23. Sambrook P (2005) Vitamin D and fractures: quo vadis ? Lancet 365:1599–1600

    Article  PubMed  Google Scholar 

  24. Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, Baverstock M, Birks Y, Dumville J, Francis R, Iglesias C, Puffer S, Sutcliffe A, Watt I, Torgerson DJ (2005) Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 330:1003–1006

    Article  PubMed  CAS  Google Scholar 

  25. Jackson RD, LaCroix AZ, Gass M, Wallace R, Robbins J, Lewis CE, Bassford T, et al (2006) Calcium plus vitamin D supplementation and risk of fractures. N Engl J Med 354:669–683

    Article  PubMed  CAS  Google Scholar 

  26. Lau KHW, Baylink DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65:295–306

    Article  PubMed  CAS  Google Scholar 

  27. Ringe JD, Schacht E (2004) Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int 24:189–197

    PubMed  CAS  Google Scholar 

  28. Papopoulos SG, Fraher LJ, Sandler LM, Clemens TL, Lewin IG, O’Riordan JLH (1979) 1,25-Dihydroxycholecalciferol in the pathogenesis of hypercalcemia of sarcoidosis. Lancet 1:627–631

    Article  Google Scholar 

  29. Dambacher MA, Schacht E (1996) Osteoporosis and active vitamin D metabolites. The shape of things to come. EULAR, Basle

    Google Scholar 

  30. Smith H, Anderson F, Raphael H, Crozier S, Cooper C (2004) Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial. Osteoporos Int 15:S8

    Google Scholar 

  31. Ringe JD (1998) Vitamin D deficiency and osteopathies. Osteoporos Int 8(Suppl 1):S35–S39

    PubMed  CAS  Google Scholar 

  32. Hamdy NAT, Kanis JA, Beneton MNC, Brown CB, Juttmann JR, Jordans JGM, Josse S, Meyrier A, Llins R, Fairey IT (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Brit Med J 310:358–363

    PubMed  CAS  Google Scholar 

  33. Schömig M, Lamichhane B, Ritz E (2000) Renal bone disease. In: Hosking D, Ringe JD (eds) Treatment of metabolic bone disease. Martin Dunitz, London

    Google Scholar 

  34. Ogata E (1990) Hypoparathyroidism: practice and theoretical background for 1α-OH-D treatment. Bone Miner 9:229–232

    Article  PubMed  CAS  Google Scholar 

  35. Davies M (2000) Treatment of osteomalacia. In: Hosking D, Ringe JD (eds) Treatment of metabolic bone disease. Martin Dunitz, London

    Google Scholar 

  36. Scharla SH, Schacht E, Lempert UG (2005) Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J Rheumatol 32:26–32

    Google Scholar 

  37. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stahelin HB (2004) Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 52:230–236

    Article  PubMed  Google Scholar 

  38. Gallagher JC (2004) The effects of calcitriol on falls and fractures and physical performance test’s. J Steroid Biochem Mol Biol 89–90:497–501

    Article  PubMed  CAS  Google Scholar 

  39. Ichikawa F, Sato K, Nanjo M, Nishi Y, Shinki T, Takahahi N, Suda T (1995) Mouse primary osteoblasts express vitamin D 25-hydroxylase mRNA and convert 1α,25-dihydroxyvitamin D3. Bone 16:129–135

    Article  PubMed  CAS  Google Scholar 

  40. Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masud Y, Hisihiya A, Ishikura N, Higashi S, Uchida Y, Saito M, Ito M, Ogata E, Watanabe K, Ikeda K (2002) Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 17:622–629

    Article  PubMed  CAS  Google Scholar 

  41. Runge M, Schacht E (2005) Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Musculoskelet Neuronal Interact 5:127–134

    PubMed  CAS  Google Scholar 

  42. Ones K, Schacht E, Dukas L, Caglar N (2007) Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Int J Epidemiol 4(1)

  43. Kataxaki E, Koulouris G, Marketos G, Fragakis N, Georgiadis AE (2004) Combined treatment of alendronate plus alphacalcidol on bone mass in postmenopausal osteoporosis. Calcif Tissue Int 74:S87–S88

    Google Scholar 

  44. Bock O, Boerst H, Runge M, Armbrecht G, Martus P, Schacht E, Hashimoto J, Felsenberg D (2007) Effects of alfacalcidol and alendronate on bone in previously untreated postmenopausal women with osteopenia or osteoporosis: one year interim subgroup analysis of the alfa study. Bone 40:S253

    Google Scholar 

  45. Masud T, Mulcahy B, Thompson AV, Donnelly S, Keen RW, Doyle DV, Spector TD (1998) Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 57:346–349

    PubMed  CAS  Google Scholar 

  46. Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M (2003) Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. J Orthop Sci 8:532–537

    Article  PubMed  Google Scholar 

  47. Shiota E, Tsuchiya K, Yamaoka K, Kawano O (2001) Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alfacalcidol in postmenopausal osteoporosis. J Orthop Sci 6:133–136

    Article  PubMed  CAS  Google Scholar 

  48. Ringe JD (2001) Osteoporosis in dialogue. 100 questions–100 answers. Thieme, Stuttgart

    Google Scholar 

  49. Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL (2003) Bone mineral and collagen quality in numeri of ovariectomized cynomolgus monkeys given rhPTH(1–34) for 18 months. J Bone Miner Res 18:769–775

    Article  PubMed  CAS  Google Scholar 

  50. Fujita T, Fukase M, Shimada T, Yamamoto H (1992) Treatment of established osteoporosis with 1α-(OH)-vitamin D3 and low dose intermittent elcalcitonin (eel calcitonin derivative). JBBM 10:37–40

    Google Scholar 

  51. Ushiroyama T, Ikeda A, Sakai M, Higashiyama T, Ueki M (2001) Effects of combined use of calcitonin and 1α-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas 40:229–238

    Article  PubMed  CAS  Google Scholar 

  52. Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618–3628

    Article  PubMed  CAS  Google Scholar 

  53. Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T (2003) Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 14:741–749

    Article  PubMed  CAS  Google Scholar 

  54. Gorai I, Tanaka Y, Iwacki Y (2006) Raloxifene when combined with 1α(OH)vitamin D more greatly suppresses bone turnover and increases bone density than when used alone in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Res 21(Suppl 1):S186

    Google Scholar 

  55. Ringe JD, Farahmand P, Schacht E, Rozenal A (2007) Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-trial). Rheumatol Int 27:425–428

    Article  CAS  PubMed  Google Scholar 

  56. Barone A, Giusti A, Piolu G, Girasole G, Razzano M, Palummeri E, Bianchi G (2007) Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc 55:752–757

    Article  PubMed  Google Scholar 

  57. Amin S, LaValley MP, Simms RW, Felson DT (1999) The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 42:1740–1751

    Article  PubMed  CAS  Google Scholar 

  58. Richy F, Ethgen O, Bruyere O, Reginster J-Y (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301–310

    Article  PubMed  CAS  Google Scholar 

  59. Richy F, Schacht E, Bruyère O, Ethgen O, Gourlay M, Reginster JY (2005) Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures. A comparative meta-analysis. Calcif Tissue Int 76:176–186

    Article  PubMed  CAS  Google Scholar 

  60. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24:63–70

    Article  PubMed  CAS  Google Scholar 

  61. Reginster JY, Kuntz D, Verdicht W, Wouters M, Guillevin L, Menkes C-J, et al (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Bone 9:75–81

    CAS  Google Scholar 

  62. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, et al (2000) Prevention of corticosteroid-induced osteoporosis by alphacalcidol. Z Rheumatol 59(Suppl 1):48–61

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Clinic 4 (Rheumatology, Osteology), Leverkusen Clinic, University of Cologne, Leverkusen, D-51375, Germany

    J. D. Ringe

  2. ZORG, Zürich Osteoporosis Research Group, Zollikerberg, Switzerland

    E. Schacht

Authors
  1. J. D. Ringe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Schacht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. D. Ringe.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ringe, J.D., Schacht, E. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Rheumatol Int 28, 103–111 (2007). https://doi.org/10.1007/s00296-007-0422-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-007-0422-6

Keywords

  • Vitamin D
  • Alfacalcidol
  • Alendronate
  • Osteoporosis
  • Combined treatments

Search

Navigation